Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury.

Hasegawa S, Susaki EA, Tanaka T, Komaba H, Wada T, Fukagawa M, Ueda HR, Nangaku M.

Kidney Int. 2019 Jul;96(1):129-138. doi: 10.1016/j.kint.2019.02.011. Epub 2019 Apr 9.

PMID:
30979565
2.

A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy.

Kimura M, Toyoda M, Saito N, Kaneyama N, Miyatake H, Tanaka E, Komaba H, Hara M, Fukagawa M.

J Diabetes Res. 2019 Feb 17;2019:9475637. doi: 10.1155/2019/9475637. eCollection 2019.

3.

The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels.

Sato T, Komaba H, Nagatani T, Watanabe T, Kishida Y, Fukagawa M.

J Endocr Soc. 2018 Nov 14;3(1):52-61. doi: 10.1210/js.2018-00223. eCollection 2019 Jan 1.

4.

Additional evidence for the role of parathyroid hormone in adipose tissue browning.

Fajol A, Komaba H.

EBioMedicine. 2019 Feb;40:3-4. doi: 10.1016/j.ebiom.2019.01.026. Epub 2019 Jan 20. No abstract available.

5.

[Secondary osteoporosis. Disordered bone metabolism in chronic kidney disease.]

Nakagawa Y, Komaba H.

Clin Calcium. 2018;28(12):1611-1618. doi: CliCa181216111618. Japanese.

PMID:
30487325
6.

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti-Platelet Activation Membrane Dialyzer in Hemodialysis Patients.

Kakuta T, Ishida M, Komaba H, Suzuki H, Fukagawa M.

Ther Apher Dial. 2019 Apr;23(2):133-144. doi: 10.1111/1744-9987.12759. Epub 2018 Oct 11.

PMID:
30311350
7.

Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Yamamoto S, Karaboyas A, Komaba H, Taniguchi M, Nomura T, Bieber BA, De Sequera P, Christensson A, Pisoni RL, Robinson BM, Fukagawa M.

BMC Nephrol. 2018 Oct 5;19(1):253. doi: 10.1186/s12882-018-1056-5.

8.

Energy sensor as a new regulator of FGF23 synthesis.

Komaba H.

Kidney Int. 2018 Sep;94(3):453-455. doi: 10.1016/j.kint.2018.05.008.

PMID:
30143064
9.

[Fragility Fractures in Hemodialysis Patients. Loss of kidney function and system for calcium homeostasis.]

Komaba H.

Clin Calcium. 2018;28(8):1057-1063. doi: CliCa180810571063. Japanese.

PMID:
30049914
10.

Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients.

Tanaka M, Komaba H, Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):242-245. doi: 10.1111/1744-9987.12685. Epub 2018 May 16. Review.

PMID:
29767854
11.

Secondary Hyperparathyroidism and Protein-Energy Wasting in End-Stage Renal Disease.

Komaba H, Fukagawa M.

Ther Apher Dial. 2018 Jun;22(3):246-250. doi: 10.1111/1744-9987.12683. Epub 2018 Apr 30. Review.

PMID:
29707907
12.

Role of Klotho in bone and implication for CKD.

Komaba H, Lanske B.

Curr Opin Nephrol Hypertens. 2018 Jul;27(4):298-304. doi: 10.1097/MNH.0000000000000423. Review.

PMID:
29697410
13.

Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate.

Komaba H, Kakuta T, Wada T, Hida M, Suga T, Fukagawa M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):318-325. doi: 10.1093/ndt/gfy090.

PMID:
29672760
14.

Magnesium as a new player in CKD: too little is as bad as too much?

Hamano N, Komaba H, Fukagawa M.

Kidney Int. 2017 Nov;92(5):1034-1036. doi: 10.1016/j.kint.2017.05.032.

PMID:
29055421
15.

Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism.

Watanabe H, Sugimoto R, Ikegami K, Enoki Y, Imafuku T, Fujimura R, Bi J, Nishida K, Sakaguchi Y, Murata M, Maeda H, Hirata K, Jingami S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T.

Biochem Pharmacol. 2017 Dec 1;145:192-201. doi: 10.1016/j.bcp.2017.08.016. Epub 2017 Aug 24.

PMID:
28843775
16.

Chronic Kidney Disease-Mineral and Bone Disorder in Asia.

Fukagawa M, Komaba H.

Kidney Dis (Basel). 2017 Jul;3(1):1-7. doi: 10.1159/000470909. Epub 2017 Apr 13. Review.

17.

Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.

Komaba H, Wang M, Taniguchi M, Yamamoto S, Nomura T, Schaubel DE, Smith AR, Zee J, Karaboyas A, Bieber B, Fukagawa M, Tentori F.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1489-1497. doi: 10.2215/CJN.13091216. Epub 2017 Jul 19.

18.

Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.

Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T.

J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):735-747. doi: 10.1002/jcsm.12202. Epub 2017 Jun 12.

19.

Klotho expression in osteocytes regulates bone metabolism and controls bone formation.

Komaba H, Kaludjerovic J, Hu DZ, Nagano K, Amano K, Ide N, Sato T, Densmore MJ, Hanai JI, Olauson H, Bellido T, Larsson TE, Baron R, Lanske B.

Kidney Int. 2017 Sep;92(3):599-611. doi: 10.1016/j.kint.2017.02.014. Epub 2017 Apr 8.

PMID:
28396120
20.

Resurgence of parathyroidectomy: evidence and outcomes.

Komaba H, Nakamura M, Fukagawa M.

Curr Opin Nephrol Hypertens. 2017 Jul;26(4):243-249. doi: 10.1097/MNH.0000000000000326. Review.

PMID:
28375871
21.

Etelcalcetide for the treatment of secondary hyperparathyroidism.

Hamano N, Komaba H, Fukagawa M.

Expert Opin Pharmacother. 2017 Apr;18(5):529-534. doi: 10.1080/14656566.2017.1303482. Epub 2017 Mar 15. Review.

PMID:
28277829
22.

Effects of klotho deletion from bone during chronic kidney disease.

Kaludjerovic J, Komaba H, Lanske B.

Bone. 2017 Jul;100:50-55. doi: 10.1016/j.bone.2017.02.006. Epub 2017 Feb 20. Review.

23.

Klotho expression in long bones regulates FGF23 production during renal failure.

Kaludjerovic J, Komaba H, Sato T, Erben RG, Baron R, Olauson H, Larsson TE, Lanske B.

FASEB J. 2017 May;31(5):2050-2064. doi: 10.1096/fj.201601036R. Epub 2017 Feb 9.

PMID:
28183805
24.

Management of secondary hyperparathyroidism: how and why?

Komaba H, Kakuta T, Fukagawa M.

Clin Exp Nephrol. 2017 Mar;21(Suppl 1):37-45. doi: 10.1007/s10157-016-1369-2. Epub 2017 Jan 2. Review.

PMID:
28044233
25.

Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism.

Sugimoto R, Watanabe H, Ikegami K, Enoki Y, Imafuku T, Sakaguchi Y, Murata M, Nishida K, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T.

Kidney Int. 2017 Mar;91(3):658-670. doi: 10.1016/j.kint.2016.09.041. Epub 2016 Dec 15.

PMID:
27988213
26.

The Prevalence of 25-hydroxyvitamin D Deficiency in Japanese Patients with Diabetic Nephropathy.

Kondo M, Toyoda M, Miyatake H, Tanaka E, Koizumi M, Komaba H, Kimura M, Umezono T, Fukagawa M.

Intern Med. 2016;55(18):2555-62. doi: 10.2169/internalmedicine.55.6346. Epub 2016 Sep 15.

27.

[113th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: Mineral Metabolism in Chronic Kidney Disease].

Fukagawa M, Komaba H.

Nihon Naika Gakkai Zasshi. 2016 Sep;105(9):1784-8. Japanese. No abstract available.

PMID:
30169952
28.

[The expanding concept of CKD-MBD].

Komaba H.

Clin Calcium. 2016 Sep;26(9):1253-60. doi: CliCa160912531260. Review. Japanese.

PMID:
27561339
29.

A Prospective Multicenter Randomized Controlled Study on Interleukin-6 Removal and Induction by a new Hemodialyzer With Improved Biocompatibility in Hemodialysis Patients: A Pilot Study.

Kakuta T, Komaba H, Takagi N, Takahashi Y, Suzuki H, Hyodo T, Nagaoka M, Tanaka R, Iwao S, Ishida M, Kobayashi H, Saito A, Fukagawa M.

Ther Apher Dial. 2016 Dec;20(6):569-578. doi: 10.1111/1744-9987.12454. Epub 2016 Aug 8.

PMID:
27501003
30.

[Targeted therapy for mineral and bone disorder].

Komaba H, Fukagawa M.

Nihon Jinzo Gakkai Shi. 2016;58(4):581-6. Japanese. No abstract available.

PMID:
27416702
31.

Phosphate-a poison for humans?

Komaba H, Fukagawa M.

Kidney Int. 2016 Oct;90(4):753-63. doi: 10.1016/j.kint.2016.03.039. Epub 2016 Jun 7. Review.

PMID:
27282935
32.

[Treatment of CKD-MBD targeting the parathyroid gland].

Isozaki Y, Komaba H.

Clin Calcium. 2016 Jun;26(6):895-903. doi: CliCa1606895903. Japanese.

PMID:
27230846
33.

PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer.

Kir S, Komaba H, Garcia AP, Economopoulos KP, Liu W, Lanske B, Hodin RA, Spiegelman BM.

Cell Metab. 2016 Feb 9;23(2):315-23. doi: 10.1016/j.cmet.2015.11.003. Epub 2015 Dec 6.

34.

The Authors Reply.

Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M.

Kidney Int. 2015 Sep;88(3):638-9. doi: 10.1038/ki.2015.218. No abstract available.

35.

Cinacalcet and Clinical Outcomes in Dialysis.

Komaba H, Fukagawa M.

Semin Dial. 2015 Nov-Dec;28(6):594-603. doi: 10.1111/sdi.12413. Epub 2015 Aug 12. Review.

PMID:
26265359
36.

Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.

Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M.

Kidney Int. 2015 Aug;88(2):350-9. doi: 10.1038/ki.2015.72. Epub 2015 Mar 18.

37.

[Regulation of parathyroid hormone secretion and pathogenesis of secondary hyperparathyroidism].

Komaba H.

Nihon Jinzo Gakkai Shi. 2014;56(8):1201-9. Review. Japanese. No abstract available.

PMID:
25551980
38.

[New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?].

Komaba H.

Clin Calcium. 2014 Dec;24(12):1771-8. doi: CliCa141217711778. Review. Japanese.

PMID:
25423921
39.

Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.

Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M.

Nephrol Dial Transplant. 2015 Jan;30(1):107-14. doi: 10.1093/ndt/gfu335. Epub 2014 Nov 23.

PMID:
25422311
40.

Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder.

Goto S, Komaba H, Fukagawa M, Nishi S.

Kidney Int Suppl (2011). 2013 Dec;3(5):457-461. Review.

41.

Case of generalized pustular psoriasis with end-stage renal disease successfully treated with granulocyte monocyte apheresis in combination with hemodialysis.

Mabuchi T, Manabe Y, Yamaoka H, Ota T, Kato M, Ikoma N, Kusakabe Y, Komaba H, Ozawa A.

J Dermatol. 2014 Jun;41(6):521-4. doi: 10.1111/1346-8138.12501. Epub 2014 May 10.

PMID:
24815562
42.

Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analyses.

Tatsumi R, Komaba H, Kanai G, Miyakogawa T, Sawada K, Kakuta T, Fukagawa M.

Nephron Clin Pract. 2013;124(3-4):224-31. doi: 10.1159/000357951. Epub 2014 Feb 4.

PMID:
24503607
43.

Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism.

Takahashi H, Komaba H, Takahashi Y, Sawada K, Tatsumi R, Kanai G, Suzuki H, Kakuta T, Fukagawa M.

J Clin Endocrinol Metab. 2014 Apr;99(4):E652-8. doi: 10.1210/jc.2013-4050. Epub 2014 Jan 29.

PMID:
24476081
44.

Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.

Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T, Kurita N, Fukuma S, Akizawa T, Fukuhara S.

Am J Kidney Dis. 2014 Jun;63(6):979-87. doi: 10.1053/j.ajkd.2013.08.011. Epub 2013 Oct 8.

PMID:
24119541
45.

p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways.

Tanaka H, Iwasaki Y, Yamato H, Mori Y, Komaba H, Watanabe H, Maruyama T, Fukagawa M.

Bone. 2013 Oct;56(2):347-54. doi: 10.1016/j.bone.2013.07.002. Epub 2013 Jul 10.

PMID:
23851293
46.

Dialysis: Effect of cinacalcet on survival--the saga continues.

Komaba H, Fukagawa M.

Nat Rev Nephrol. 2013 Aug;9(8):435-6. doi: 10.1038/nrneph.2013.130. Epub 2013 Jul 2. No abstract available.

PMID:
23820810
47.

Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsukamoto Y, Tsubakihara Y, Tomo T, Hirakata H, Akizawa T; CKD-MBD Guideline Working Group; Japanese Society for Dialysis Therapy.

Ther Apher Dial. 2013 Jun;17(3):247-88. doi: 10.1111/1744-9987.12058. No abstract available.

PMID:
23735142
48.

Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.

Koizumi M, Komaba H, Fukagawa M.

Contrib Nephrol. 2013;180:110-23. doi: 10.1159/000346791. Epub 2013 May 3. Review.

PMID:
23652554
49.

Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.

Fukagawa M, Komaba H, Kakuta T.

Expert Opin Pharmacother. 2013 May;14(7):863-71. doi: 10.1517/14656566.2013.783017. Epub 2013 Mar 24. Review.

PMID:
23521343
50.

Vitamin D and secreted Klotho: a long-awaited panacea for vascular calcification?

Komaba H, Fukagawa M.

Kidney Int. 2012 Dec;82(12):1248-50. doi: 10.1038/ki.2012.338.

Supplemental Content

Loading ...
Support Center